EW
Edwards Lifesciences Corp
86.30$
+0.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 65.1% | 50.4% | 49.7% | 44.5% | 43.0% | 46.0% | 42.7% | 37.4% | 37.3% | 43.1% | 48.1% | 49.2% | |
| 18.6% | 17.7% | 20.6% | 14.4% | 13.4% | 18.2% | 16.3% | 10.1% | 9.3% | 12.1% | 23.3% | 21.5% | |
| 40.8% | 30.2% | 28.2% | 23.5% | 18.0% | 23.4% | 19.4% | 17.3% | 14.7% | 17.4% | 30.5% | 30.9% | |
| 9.2% | 8.5% | 9.2% | 8.4% | 10.1% | 9.2% | 8.3% | 7.8% | 8.4% | 8.8% | 5.6% | 6.7% | |
| 8.4% | 8.4% | 8.8% | 9.7% | 11.4% | 9.9% | 11.1% | 8.5% | 10.6% | 9.6% | 8.3% | 8.2% | |
| 12.6% | 11.9% | 12.9% | 11.9% | 16.3% | 16.3% | 19.3% | 19.3% | 20.8% | 19.7% | 13.7% | 14.0% | |
| 10.7% | 15.5% | 13.9% | 19.8% | 20.9% | 18.0% | 16.2% | 13.7% | 14.0% | 12.2% | 13.6% | 12.9% | |
| 0.7% | 5.1% | 4.5% | 8.2% | 6.4% | 5.2% | 4.6% | 3.8% | 3.4% | 4.3% | 9.0% | 8.2% | |
| 37.8% | 38.3% | 41.9% | 47.4% | 41.0% | 36.1% | 36.8% | 31.4% | 30.0% | 28.2% | 22.9% | 24.5% | |
| 12.3% | 11.7% | 11.8% | 24.6% | 16.5% | 13.9% | 12.4% | 12.1% | 12.3% | 12.8% | 11.5% | 13.2% | |
| 17.0% | 14.7% | 18.2% | 10.5% | 0.0% | 0.4% | 0.4% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | |
| 1.7% | 1.6% | 2.2% | 2.0% | 2.5% | 2.8% | 2.7% | 2.4% | 2.4% | 2.0% | 1.5% | 1.7% | |
| 17.0% | 14.7% | 18.2% | 7.7% | 11.2% | 9.2% | 8.2% | 7.0% | 7.2% | 6.4% | 4.6% | 4.4% | |
| 62.2% | 61.7% | 58.1% | 52.6% | 59.0% | 63.9% | 63.2% | 68.6% | 70.0% | 71.0% | 76.6% | 75.5% | |
| 80.6% | 82.2% | 86.6% | 35.1% | 50.6% | 57.7% | 63.1% | 71.4% | 91.5% | 96.0% | 100.9% | 104.0% | |
| 18.5% | 16.3% | 14.5% | 11.4% | 12.0% | 9.8% | 8.7% | 7.4% | 7.5% | 6.5% | 4.6% | 4.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.